Salicylamide
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Salicylamide: From Headache Disorder to Pharyngitis
One-Sentence Summary
Salicylamide is a salicylate-class analgesic and antipyretic, originally used for headache disorders. The TxGNN model predicts it may be effective for Pharyngitis, but there are 0 registered clinical trials and only 1 publication (a 1953 historical report on a combination product), so the evidence is weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Headache disorder (from the knowledge graph; the Singapore licences carry no indication text) |
| Predicted New Indication | Pharyngitis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, salicylamide is a salicylate-class analgesic and antipyretic with weak anti-inflammatory activity. Its use for pain relief in headache is established, and mechanistically it may be applicable to sore throat as symptomatic relief.
Pharyngitis and headache share pain as the main symptom, so a symptomatic analgesic effect is plausible. However, this is a loose link. The only supporting publication is a 1953 report on catarrhal tonsillitis in infants using salicylamide combined with sodium p-aminobenzoate. Its design is uncertain, and the effect of salicylamide alone cannot be separated out. No modern trials exist.
The other predictions are weaker still. Nasal cavity disease, acute laryngopharyngitis, and several others are model predictions only. For allergic urticaria and common cold, the retrieved literature concerns safety (hypersensitivity reactions, overdose toxicity, and drug-induced hemolytic anemia) rather than efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 13060598 | 1953 | Case series / clinical report | Gazzetta medica italiana | Treatment of catarrhal tonsillitis in infants with salicylamide combined with sodium p-aminobenzoate. Historical, no abstract available, and the effect of salicylamide alone cannot be isolated. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN08055P | Semor Pain and Fever Relief Capsules | Capsule | Not stated |
| SIN05768P | Con-Z-Lin Tablet | Tablet, sugar coated | Not stated |
| SIN02859P | Consu Capsule | Capsule | Not stated |
| SIN03369P | Fongtit 600 Capsule | Capsule | Not stated |
All four are valid single-ingredient licences held by Sunward Pharmaceutical Private Limited, with oral dosage forms.
Safety Considerations
- Contraindications (from the knowledge graph, not label text): The drug-disease contraindication links include:
- Cardiovascular: hypertension, hypotension
- Liver, kidney and gallbladder: liver failure, liver disease, kidney disease, gallbladder disease
- Blood: thrombocytopenia, blood coagulation disease, hemophilia, anaemia (including macrocytic)
- Gastrointestinal: peptic ulcer disease, gastritis, inflammatory bowel disease, Clostridium difficile colitis
- Respiratory: COPD
- Endocrine and metabolic: diabetes mellitus, diabetic ketoacidosis, hypothyroidism (including myxedema and congenital hypothyroidism), potassium deficiency, gout
- Neurological and other: epilepsy, insomnia, benign prostatic hyperplasia, substance abuse/dependence
- Safety signals in the retrieved literature:
- Overdose toxicity (1996 report).
- Drug-induced hemolytic anemia with agranulocytosis after a cold combination product containing salicylamide (1996 case report).
- Salicylates and NSAIDs can exacerbate allergic conditions such as urticaria.
- Salicylates carry safety concerns in neonates and young children, which matters for the infant tonsillitis evidence.
- Drug Interactions: No interaction data were found.
Please refer to the package insert for label warnings.
Conclusion and Next Steps
Decision: Hold
Rationale: The high TxGNN score is not backed by modern evidence. The only pharyngitis publication is a 1953 combination-product report, there are no registered trials, and the safety signals, especially in children, are a concern. A symptomatic analgesic effect on sore throat is plausible, but it would not be a meaningful new indication beyond existing pain and fever relief.
To proceed, the following is needed:
- Package insert warnings and contraindications for the Singapore products (currently missing and blocking safety screening)
- Mechanism of action data
- Approved indication text for the four Singapore licences, to confirm whether sore throat is already covered
- Controlled clinical evidence for salicylamide alone in pharyngitis or sore throat
- A paediatric safety assessment, given the infant population in the historical report and the haematological and hypersensitivity signals
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.